Once Royal Philips has battled through the practicalities of its Respironics remediation issues and factored in the uncertainties in the China market, there are positive business trends to look forward to.
Amid China Weakness Philips Stresses Value Creation And Innovation Upside
Top-Three Imaging Concern Looks To Put Respironics Issues In The Past
Philips, the last of the global top-three imaging companies to report 2024 financial results, said the soft China market put the brakes on its growth. The regional outlook for early 2025 is no different, and US-China tariffs will present another challenge.
More from Business
More from Medtech Insight
• By
Medical devices, diagnostics, and equipment face tariffs announced by President Donald Trump, despite industry pleas for exemption. The tariffs, ranging from 10%-49%, impact most countries trading with the US, potentially hindering innovation and increasing costs in the medtech sector.
• By
The US FDA has published its final document to guide sponsors on using sex-specific data in designing clinical trials of medical devices. However, the guidance removes all references to gender that appeared in January’s draft guidance, released before the Trump administration took office.